Adenosine Deaminase Severe Combined Immune Deficiency
Conditions
Keywords
Gene Therapy, Hematopoietic Stem Cell, Lentiviral Vector, Reduced Intensity Conditioning with Busulfan
Brief summary
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
Detailed description
The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA complementary DNA (cDNA) will be used to transduce autologous CD34+ cells from Granulocyte Colony Stimulating Factor (G-CSF)/Plerixafor mobilized Peripheral Blood (mPB) of these subjects. The subjects will receive pharmacokinetically-adjusted busulfan reduced intensity conditioning prior to re-infusion of their gene-modified cells. Overall survival at two years is the primary endpoint. During the follow-up phase, the investigators aim to determine whether the cells could engraft and produce mature cells that contain and express the corrected ADA gene in the absence of pegylated adenosine deaminase (PEG-ADA) enzyme replacement therapy (ERT), which will be withheld starting on Day +30 following transplant. Efficacy studies to evaluate the level of immune reconstitution, will be performed in the two years of the study. Patients will be asked to enroll into a long-term follow-up study to reach a total of 15 years follow-up after gene therapy.
Interventions
COMBINATION_PRODUCTA cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
Sponsors
University of California, Los Angeles
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective, non-randomized Phase I/II clinical trial to assess the safety and efficacy of gene therapy for ADA SCID by transplantation of autologous mPB CD34+ hematopoietic stem and progenitor cells (HSPC) transduced by the EFS-ADA lentiviral vector.
Eligibility
Sex/Gender
ALL
Age
1 Months to No maximum
Healthy volunteers
No
Inclusion criteria
All subjects must fulfill the following criteria to be included in the study: 1. Provision of written informed consent prior to any study related procedures. In this study consent must be provided by the parents/legal guardians and, where applicable according to local laws, a signed assent from the child, 2. Subjects ≥30 days of age, 3. With a diagnosis of ADA-SCID based on: Evidence of ADA deficiency, defined as: i. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal cells to levels consistent with ADA-SCID as determined by the reference laboratory, or ii. Identified mutations in ADA alleles consistent with a severe reduction in ADA activity, Evidence of ADA-SCID based on either: i. Family history of a first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, or ii. Evidence of severe immunologic deficiency in subjects prior to the institution of immune restorative therapy, based on 1. Lymphopenia (absolute lymphocyte count (ALC) \<400 cells/mL) OR absence or low number of T cells (absolute CD3+ count \< 300 cells/mL), or 2. Severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (either \<10% of lower limit of normal controls for the diagnostic laboratory, or \<10% of the response of the normal control of the day, or stimulation index \<10), or 3. Identification of SCID by neonatal screening revealing low T Cell Receptor Excision Circles (TREC) levels. 4. Ineligible for matched family allogeneic bone marrow (BM) transplantation, defined as the absence of a medically eligible HLA-identical sibling or family donor, with normal immune function, who could serve as an allogeneic bone marrow donor. 5. Females of child-bearing age will be required to provide a negative pregnancy test 30 days prior to Visit 2. 6. Subjects and their parents/legal guardians must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period and willing to return to the clinic for the follow up evaluation as specified in the protocol.
Exclusion criteria
Subjects will not be eligible for the study if any of the following criteria is fulfilled: 1. Ineligible for autologous HSCT as per clinical site criteria 2. Other conditions which in the opinion of the Principal Investigator and/or Co Investigators, contraindicate the mobilization of peripheral blood or the leukapheresis process, the administration of busulfan and the infusion of transduced cells, or which indicate an inability of the subject or subject's parent/legal guardian to comply with the protocol 3. Hematologic abnormality, defined as: * Anemia (Hb \<8.0 g/dl). * Neutropenia (ANC \<500/mm3). Note: ANC \<500 with absence of myelodysplastic syndrome on bone marrow aspirate and biopsy and normal marrow cytogenetics are acceptable for eligibility. * Thrombocytopenia (platelet count \<50,000/mm3, at any age). * Prothrombin time or international normalized ratio (INR) and partial thromboplastin time (PTT) \>2 x upper limit of normal (ULN) (subjects with a correctable deficiency controlled on medication will not be excluded). * Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid (if available). * Prior allogeneic HSCT with cytoreductive conditioning. 4. Pulmonary abnormality, defined as: * Resting O2 saturation by pulse oximetry \<90% on room air. * Chest X-ray indicating active or progressive pulmonary disease. Note: Chest X ray indicating residual signs of treated pneumonitis is acceptable for eligibility. 5. Cardiac abnormality, defined as: * Abnormal ECG indicating cardiac pathology. * Uncorrected congenital cardiac malformation with clinical symptoms. * Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension. * Poor cardiac function as evidenced by left ventricular ejection fraction \<40% on echocardiogram. 6. Neurologic abnormality, defined as: * Significant neurologic abnormality revealed by examination. * Uncontrolled seizure disorder. 7. Renal abnormality, defined as: * Renal insufficiency: serum creatinine ≥1.2 mg/dl (106 µmol/L), or ≥3+ proteinuria. * Abnormal serum sodium, potassium, calcium, magnesium or phosphate levels at \>2 x ULN. 8. Hepatic/gastrointestinal abnormality, defined as: * Serum transaminases \>5 x ULN. * Serum bilirubin \>2 x ULN. * Serum glucose \>1.5 x ULN. 9. Oncologic disease, defined as: * Evidence of active malignant disease other than dermatofibrosarcoma protuberans (DFSP). * Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells (if anti-neoplastic therapy has been completed, a subject with a history of DFSP can be included). * Evidence of DFSP expected to be life limiting within the 5 years following the infusion of genetically corrected cells. 10. Known sensitivity to Busulfan. 11. Confirmation of an infectious disease by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) positive at time of assessment for the following: * HIV-1, * Hepatitis B, * Parvovirus B19. 12. The subject is pregnant or has a major congenital anomaly. 13. Is likely to require treatment during the study with drugs that are not permitted by the study protocol. 14. The subject has previously received another form of gene therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival | 24 months | The primary study outcome will be to determine survival for all subjects 2 years after gene therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate Safety from clinical adverse events. | 24 months | Evaluate safety of the treatment by recording clinical adverse events (AE). |
| Evaluate Safety from replication competent lentivirus by quantitative polymerase chain reaction (qPCR) assay. | 24 months | Evaluate safety by recording incidents of replication competent lentivirus by qPCR assay.. |
| Evaluate Safety from vector-related clonal expansion by non-restrictive Linear Amplification Polymerase Chain Reaction (nrLAM-PCR) | 24 months | Evaluate safety by recording incidence of vector-related clonal expansion by nrLAM-PCR |
| Record event free survival at 24 months | 24 months | Record Event Free Survival as a definition of "failure" of the therapy. Event-free survival is defined as the proportion of subjects alive with no "event", an "event" being the resumption of PEG-ADA ERT or the need for a rescue allogeneic hematopoietic stem cell transplant (HSCT), or death. |
| Determine incidence of Infection over two years after gene therapy | 24 months | Determine the incidence and severity of infections post-gene therapy (subsequent to hematopoietic reconstitution). Over 2 years, record the incidence of hospitalizations or outpatient-based treatments for systemic bacterial, fungal, or viral infections (including, but not limited to Cytomegalovirus (CMV) infections). |
| Neuro-developmental Outcomes by neurodevelopmental testing (subjects 5-7 yeas of age) | 24 months | Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (5- 7 years of age) at baseline and 2 years post-gene therapy - Wechsler Scale of Intelligence |
| Neuro-developmental Outcomes by neurodevelopmental testing (subjects 1 year -42 month of age) | 24 months | Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (1 year to 42 months of age) at baseline and 2 years post-gene therapy - : Bayley Scale of Infant Development |
| Neuro-developmental Outcomes by Brain Stem Evoked Response (BAER) testing | 24 months | Measure neuro-developmental status post-gene therapy - Perform Brainstem Auditory Evoked Response test at baseline and at 2 years. |
| Cessation of immunoglobulin replacement therapy (IgRT). | 24 months | Record time post-gene therapy that immunoglobulin replacement therapy (IgRT) is stopped based on defined criteria. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSatiro De Oliveira, MD
Assistant Professor
Outcome results
None listed